普洛药业: 关于回购股份注销完成暨股份变动的公告

Core Viewpoint - The company has completed the cancellation of repurchased shares, reducing its total share capital from 1,169,323,576 shares to 1,158,443,576 shares, which is expected to enhance earnings per share and improve shareholder returns [1][2][3] Summary by Sections 1. Approval and Implementation of Share Repurchase - The company approved a share repurchase plan on March 27, 2024, allowing for the repurchase of shares at a price not exceeding RMB 20 per share, with a total repurchase fund of at least RMB 153 million [1][2] - The actual repurchase involved 10,880,000 shares, accounting for 0.93% of the total share capital, with a total transaction amount of approximately RMB 153 million [1][2] 2. Cancellation of Repurchased Shares - The cancellation of the repurchased shares was confirmed by the China Securities Depository and Clearing Corporation on June 19, 2025, in compliance with relevant laws and regulations [2][3] - The number of shares canceled was 10,880,000, which represented 0.93% of the total share capital before cancellation [2] 3. Changes in Shareholding Structure - Following the cancellation, the total number of shares decreased to 1,158,443,576, with the structure remaining compliant with listing requirements [2][3] - The proportion of unrestricted circulating shares slightly decreased from 99.9628% to 99.9624% after the cancellation [2] 4. Impact of Share Cancellation - The cancellation is expected to enhance the company's earnings per share and improve returns for shareholders without significantly affecting the company's financial status or future development [3] - The cancellation will not harm the interests of shareholders, particularly minority shareholders, and will not lead to changes in the controlling shareholder or actual controller [3] 5. Follow-up Arrangements - The company will proceed with necessary changes in business registration and articles of association as per legal requirements following the completion of the share cancellation [3]